Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: Experience from clinical practice of four tertiary hospitals

Abstract

Despite brodalumad demonstrated efficacy in clinical trials, real‐world data reflecting clinical benefits in unselected patient populations treated in routine clinical practice are limited. Thus, we performed a longitudinal, retrospective, real‐world analysis assessing the long‐term clinical benefits of patients with moderate‐to‐severe psoriasis treated with brodalumab in Greece in the long term (up to 24 months). Main efficacy assessments included changes from baseline in the psoriasis area and severity index (PASI) and proportions of patients achieving at least 50%, 75%, 90% and 100% reduction from baseline in PASI scores (PASI50, PASI75, PASI90 and PASI100) at different timepoints up to 24 months. Other endpoints included changes in the dermatology life quality index (DLQI) and body surface area (BSA) involvement. Data from medical records of 180 patients with moderate‐to‐severe psoriasis treated with brodalumab for up to 24 months were assessed. Following treatment, mean [standard deviation (SD)] PASI scores were decreased across all visits compared to baseline (p < 0.001). The proportion of patients achieving PASI50, PASI75, PASI90 or PASI100 were high as early as at month 1 and consistently tended to increase over time, mainly during the first 6 months. Improvements on disease severity were further reflected by reductions from baseline on BSA scores across all visits (p < 0.001). Concurrent improvements on DLQI scores were observed across all visits (p < 0.001). This retrospective analysis provides real‐world evidence supporting the long‐term efficacy profile of brodalumab in Greek patients with moderate‐to‐severe psoriasis treated in standard clinical practice, which is characterized by a rapid onset of action generally sustained over time.

Brodalumab in plaque psoriasis: Real‐world data on effectiveness, safety and clinical predictive factors of initial response and drug survival over a period of 104 weeks

“…Overall, any previous exposure to IL‐17 inhibitors should not discourage the clinician to initiate brodalumab treatment. The positive effect of early response in drug survival has also been highlighted in other studies 19‐28 …”

“…In our cohort, PASI≤3 response rates were equivalent (88.9/89.8/92.6% at 12/24/52 weeks, respectively). In another recently published Greek study evaluating 185 patients with psoriasis under brodalumab, PASI90 and PASI100 responses at week 52 were lower (approximately 71.1% and 54.0%, respectively) 19 …”

Brodalumab: Efficacy, safety, and survival in mid‐term (52 weeks) on real clinical practice in Andalucia, Spain

“…In clinical trials, <2% of patients experienced neutropenia or candidiasis, and none required discontinuation of treatment, but in our series, five patients did it according to the clinician recommendation. This is applicable to all published clinical practice series 5–9 . Of special interest is the psychological evaluation and psychiatric comorbidities in patients who have received brodalumab and that in no case did it mean abandonment of treatment.…”

“…This is applicable to all published clinical practice series. [5][6][7][8][9] Of special interest is the psychological evaluation and psychiatric comorbidities in patients who have received brodalumab and that in no case did it mean abandonment of treatment.…”

“…In this series, the evaluation of efficacy at 24 weeks is established as a secondary endpoint, where 80.8%, 69.2%, and 55.1%, respectively, reach PASI75, PASI90, and PASI90 (with almost equivalent data in percentage of patients with PASI < 5, PASI < 3, and PASI < 1) and with no substantial differences between weeks 12 and 24. On the other hand, the Greek series led by Tampouratzi 8 shows a 52 week follow‐up of 180 patients. In this series, the percentage that reaches PASI75, PASI90, and PASI90 is 86.7%, 70.7%, and 53.3%, resulting in line with the Italian one but with a larger number of patients, a smaller number of bio‐naive patients (8.33%) and a greater number of patients with psoriatic arthropathy (20%), two factors that, a priori, could negatively influence the percentage of patients who achieve better results.…”